A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women

Journal of Women's Health

Volumn 24, Issue 4, 2015, Pages 281-290

  Kornstein, Susan G ^a   Clayton, Anita H ^b   Bao, Weihang ^c   Guico Pabia, Christine J ^d  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c PFIZER INC   (United States)

^d CGP Strategic Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESVENLAFAXINE; PLACEBO; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLIMACTERIUM; CONTROLLED STUDY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MENOPAUSE RATING SCALE; MULTICENTER STUDY (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; SHEEHAN DISABILITY SCALE; ADVERSE DRUG REACTION; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MENOPAUSE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84928045981     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2014.4900     Document Type: Article

References (47)

1. Patten SB, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J Affect Disord 2009;117:S5-S14.
2. Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004;420:21-27.
3. Kessler RC. Epidemiology of women and depression. J Affect Disord 2003;74:5-13.
4. Deecher D, Andree TH, Sloan D, Schechter LE. From menarche to menopause: Exploring the underlying biology of depression in women experiencing hormonal changes. Psychoneuroendocrinology 2008;33:3-17.
5. Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Arch Gen Psychiatry 2006;63:385-390.
6. Freeman EW, Sammel MD, Lin H, Nelson DB. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry 2006;63:375-382.
7. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000;157: 1445-1452.
8. Martenyi F, Dossenbach M, Mraz K, Metcalfe S. Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile. Eur Neuropsychopharmacol 2001;11:227-232.
9. Khan A, Brodhead AE, Schwartz KA, Kolts RL, Brown WA. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 2005;25:318-324.
10. Thase ME, Entsuah R, Cantillon M, Kornstein SG. Relative antidepressant efficacy of venlafaxine and SSRIs: Sex-age interactions. J Womens Health (Larchmt) 2005;14:609-616.
11. Grigoriadis S, Kennedy SH, Bagby RM. A comparison of antidepressant response in younger and older women. J Clin Psychopharmacol 2003;23:405-407.
12. Parker G, Parker K, Austin MP, Mitchell P, Brotchie H. Gender differences in response to differing antidepressant drug classes: Two negative studies. Psychol Med 2003;33:1473-1477.
13. Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE. Duloxetine efficacy for major depressive disorder in male vs. female patients: Data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 2006;67:761-770.
14. Pinto-Meza A, Usall J, Serrano-Blanco A, Suarez D, Haro JM. Gender differences in response to antidepressant treatment prescribed in primary care. Does menopause make a difference? J Affect Disord 2006;93:53-60.
15. Quitkin FM, Stewart JW, McGrath PJ, et al. Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002;159:1848-1854.
16. Young EA, Kornstein SG, Marcus SM, et al. Sex differences in response to citalopram: A STAR D report. J Psychiatr Res 2009;43:503-511.
17. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer Inc., 2013.
18. Thase ME, Kornstein SG, Germain JM, Jiang Q, Guico- Pabia C, Ninan PT. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr 2009;14: 144-154.
19. Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico- Pabia CJ. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2010;71:1088-1096.
20. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebocontrolled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry 2013;74:1010-1017.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Text Revision, 4th ed. Washington, DC: American Psychiatric Publishing, 2000.
23. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134: 382-389.
24. Nesse RE. Abnormal vaginal bleeding in perimenopausal women. Am Fam Physician 1989;40:185-192.
25. Johannes CB, Crawford SL. Menstrual bleeding, hormones, and the menopausal transition. Semin Reprod Endocrinol 1999;17:299-309.
26. Mitchell ES, Woods NF, Mariella A. Three stages of the menopausal transition from the Seattle Midlife Women's Health Study: Toward a more precise definition. Menopause 2000;7:334-349.
27. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Climacteric 2001;4:267-272.
28. Astrup K, Olivarius NF, Moller S, Gottschau A, Karlslund W. Menstrual bleeding patterns in pre- and perimenopausal women: A population-based prospective diary study. Acta Obstet Gynecol Scand 2004;83:197-202.
29. Burger HG, Robertson DM, Baksheev L, Collins A, Csemiczky G, Landgren BM. The relationship between the endocrine characteristics and the regularity of menstrual cycles in the approach to menopause. Menopause 2005;12: 267-274.
30. Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: Creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005;12:128-135.
31. Randolph JF, Jr., Crawford S, Dennerstein L, et al. The value of follicle-stimulating hormone concentration and clinical findings as markers of the late menopausal transition. J Clin Endocrinol Metab 2006;91:3034-3040.
32. Guy W. Clinical Global Impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976:217-222.
33. Sheehan DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington DC American Psychiatric Association 2000 113-115.
34. Heinemann K, Ruebig A, Potthoff P, et al. The Menopause Rating Scale (MRS) scale: A methodological review. Health Qual Life Outcomes 2004;2:45.
35. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement- based care in STAR D: Implications for clinical practice. Am J Psychiatry 2006;163:28-40.
36. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR D report. Am J Psychiatry 2006;163:1905-1917.
37. Nierenberg AA. Advancing the treatment of depression with personalized medicine. J Clin Psychiatry 2012;73:e17.
38. Joffe H, Soares CN, Petrillo LF, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68:943-950.
39. Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22:94-97.
40. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial. Obstet Gynecol 2008;111:77-87.
41. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10.
42. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, for the Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.
43. Pinkerton JV, Constantine G, Hwang E, Cheng RF. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: A 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause 2013;20:28-37.
44. Bouchard P, Panay N, de Villiers TJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric 2012;15: 12-20.
45. Heinemann LA, Potthoff P, Schneider HP. International versions of the Menopause Rating Scale (MRS). Health Qual Life Outcomes 2003;1:28.
46. Kornstein SG, Clayton A, Bao W, Guico-Pabia CJ. A post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Menopause 2014;21:799-806.
47. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause 2012;19:387-395.